Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 stu...

Por Christos, Chouaid, Hervé, Le Caer, Chrystelle, Locher, Cecile, Dujon, Pascal, Thomas, Jean Bernard, Auliac, Isabelle, Monnet, Alain, Vergnenegre
Publicado em 2012

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

Por Alain Vergnenegre, Margaux Geier, Florian Guisier, Regine Lamy, Bénédicte Comet, Gwenaelle Le Garff, Pascal Do, Henri Janicot, Hugues Morel, Chantal Decroisette, Michel Andre, Lionel Falchero, Nicolas Paleiron, Isabelle Monnet, the GFPC Team
Publicado em 2020-01-01

Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival

Por Lisa Quetel, Clément Meiller, Jean‐Baptiste Assié, Yuna Blum, Sandrine Imbeaud, François Montagne, Robin Tranchant, Julien deWolf, Stefano Caruso, Marie‐Christine Copin, Véronique Hofman, Laure Gibault, Cécile Badoual, Ecaterina Pintilie, Paul Hofman, Isabelle Monnet, Arnaud Scherpereel, Françoise Le Pimpec‐Barthes, Jessica Zucman‐Rossi, Marie‐Claude Jaurand, Didier Jean
Publicado em 2020-06-01